U.S. markets open in 6 minutes

Lattice Biologics Ltd. (LBLTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0587-0.0299 (-33.75%)
At close: 2:20PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.0886
Open0.0587
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0587 - 0.0587
52 Week Range0.0131 - 0.1450
Volume20,000
Avg. Volume15,684
Market Cap8.616M
Beta (5Y Monthly)-11.80
PE Ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Lattice Unaware of Any Material Change

    Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") at the request of the Investment Industry Regulatory Organization of Canada ("IIROC"), wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and trading volume of its common shares.

  • Business Wire

    COVID19 UPDATE – Lattice Biologics Announces Cessation of Patient Recruitment

    Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announces cessation of patient recruitment for its Phase 1 study.

  • Business Wire

    Lattice Biologics Ltd. Reports Q3 2020 Results

    Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announces financial results for Q3 2020.